key: cord-0728627-5dk3pslc
authors: O'Kelly, Brendan; Vidal, Louise; Avramovic, Gordana; Broughan, John; Connolly, Stephen Peter; Cotter, Aoife G; Cullen, Walter; Glaspy, Shannon; McHugh, Tina; Woo, James; Lambert, John S
title: Assessing the impact of COVID-19 at 1 year using the SF-12 questionnaire: Data from the Anticipate longitudinal cohort study
date: 2022-03-14
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2022.03.013
sha: 1597cb17b9d0c42c317fe7aafe619b549361e8ad
doc_id: 728627
cord_uid: 5dk3pslc

Background : Few studies to date have explored HRQoL in long COVID patients. Methods : The Anticipate Study is a prospective single centre observational cohort study. Hospitalised and non-hospitalised patients were seen at a dedicated post-Covid clinic at a 2-4 month (Timepoint 1) and 7-14 month follow up (Timepoint 2). The main objectives of this study are to assess the longitudinal impact of COVID-19 in patients using the 12-item Short Form Survey (SF-12) score, a Health Related Quality of Life tool, also to identify predictors of developing Post COVID-19 Syndrome (PoCS). Also, to describe symptomatology and identify predictors of PoCS at 1 year. Results : 155 patients were enrolled, 105(68%) were female aged 43.3 (31-52) years. In total 149(96%) and 94(61%) completed follow up at median 96(76-118) days and 364 (303-398) days. The overall cohort had significantly reduced Physical Composite Score (PCS) of the SF-12 (45.39(10.58) vs 50(10), p=.02). Participants with PoCS had significantly lower scores than those without symptoms at 1 year follow up (37.2(10.4) v 46.1(10.9) p <0.001), and scores for these patients did not improve over the two Timepoints (PCS 34.95(10.5) – 37.2(10.4), p=.22). Fatigue was the most common symptom. Those with five or more symptoms at initial diagnosis had lower PCS and MCS scores at 1 year. Predictors of PoCS at 1-year were lower PCS, and higher baseline heart rate (HR) at clinic review median 3 months after COVID-19. Conclusion : PoCS patients have lower PCS scores during follow-up which did not significantly improve up to a 1-year follow up. Lower PCS scores and higher resting HR can be used in the weeks after COVID-19 can help predict those at risk of PoCS.

To date (February 2022), over 388 million infections with COVID-19 have been reported by the World Health Organization (WHO) (WHO, 2022) . International vaccination efforts have significantly reduced the risk of hospitalisation and death from COVID-19 by approximately 90% in those vaccinated(Marie Joëlle Jabagi, 2021) allowing many countries to relax other public health measures.

One less understood consequence of infection is the development of 'long COVID', a general term describing symptoms persisting four weeks after onset of acute COVID-19. The National Institute for Health and Care Excellence (NICE), the Centre for Disease Control (CDC) and the World Health Organization (WHO) have all released definitions that generally describe the persistence of symptoms after acute COVID-19; 'Post COVID-19 Syndrome' (PoCS), 'Post COVID conditions' and 'Post COVID-19 condition' (CDC, 2021 , NICE, 2020 , WHO, 2021 .All of these definitions can come under the umbrella term of long COVID, Table 1 .

Patients can have multiple symptoms and it does not appear that severity of acute is predictive of persistence of symptoms (Lopez-Leon et al., 2021) . (Dennis et al., 2020 , Townsend et al., 2021 , Townsend et al., 2020 . The quoted prevalence of long COVID in the literature varies, which may be due to heterogenous study design and small sample sizes, as many as 76% of patients have been shown to have symptoms at 6 months (Nalbandian et al., 2021) (Huang et al., 2021) . A more recent study, REACT-2, involved community patients in the United Kingdom (UK) with over 78,000 initially symptomatic participants showed 37.7% had one or more symptoms beyond 12 weeks post initial infection (Whitaker M, 2021) . Few studies describe symptomatology beyond 6 months, a report from a single centre suggest that 24% of patients have ongoing dyspnoea at a median 44 weeks (Nguyen et al.) . The scale and level of disability due to long COVID needs to be more clearly defined.

Management of long COVID in most countries is under-resourced and under-developed. In the United Kingdom (UK), steps have been taken to mitigate this by establishing over 80 clinics with a focus on multidisciplinary integrative care and dedicated studies into Long COVID (Care, 2021) . Also the United States (US) Congress have pledged $1.15 billion over four years to the National Institute of Health(NIH) to investigate the prolonged health consequences of COVID-19(NIH, 2021) .

We aim to add to this knowledge in a number of ways; Firstly by examining the prolonged impact of COVID-19 on patients using the 12-Item Short Form Survey (SF-12) Health Related Quality of Life (HRQoL) Questionnaire at 3 months (Timepoint 1) and 12 months (Timepoint 2) after acute COVID-19 symptom onset (Timepoint 0). Secondly, to identify factors that may be associated with lower SF-12 scores at 12 months; healthcare worker status, number of initial symptoms, hospitalisation, admission to intensive care, age, sex and presence of PoCS. Thirdly, to describe symptomatology in this cohort; the presence of PoCS at 12 months and identify early predictors for the persistence of PoCS at 12 months.

Methods This is a single centre prospective observational cohort study and was carried out in the Mater Misericordiae University Hospital (MMUH), a 580 bed Tertiary Hospital and site of Ireland's National Isolation unit (NIU). Patients were recruited from the 'post-COVID clinic', managed by the Infectious Diseases Department, between June and November 2020.

Patients were eligible if they had laboratory confirmed COVID-19, or in those with a clinical diagnosis of COVID-19 which requires patients to have had symptoms of acute COVID-19 including fevers, shortness of breath (SOB), cough, myalgia, anosmia or other symptoms in returning travellers or local patients at times where community transmission was known in those respective areas. All COVID-19 patients who were admitted, who were seen and diagnosed in the Emergency Department and discharged with home monitoring (as they did not meet criteria for admission), and patients referred by General Practitioners from the catchment area with COVID-19 were offered follow up appointment in the clinic.

The onset of initial symptoms is labelled 'Timepoint 0', patients were retrospectively asked about symptoms at this time and charts of hospitalised patients were reviewed. HRQoL questionnaires were completed at 2-4 month (Timepoint 1) follow up after initial symptom onset, patients were also recruited at this time. A second review was done at 7-14 months (Timepoint 2). The aim was to capture individuals around one year post Timepoint 0, a wide range of time was given for follow up to buffer the potential reduction in clinic availability due to subsequent infectious waves of COVID-19. Data collection included age, sex, date of symptom onset and confirmatory testing in those with a positive nasopharyngeal polymerase chain reaction (PCR) test, comorbidities, healthcare workers status, hospitalisation, complications, length of stay (LOS), intensive care unit (ICU) admission, need for mechanical ventilation (MV), and vital signs and were all collected from patient notes.

Results of X-ray chest and computerised tomography (CT) thoraces were collected from the electronic hospital record. Data collection was performed only by members of the research team. Data was pseudo anonymised and collected on Redcap®, an on-line password protected research tool only accessible by members of the research team. Patients were classified as having PoCS at Timepoint 2 according to NICE guidelines 'Signs and symptoms that develop during or after an infection consistent with COVID-19, continue for more than 12 weeks and are not explained by an alternative diagnosis' as this was the original definition available, as this was definition available at the time of the study (NICE, 2020).

SF-12 is a HRQoL measure which is a shortened and validated version of the SF-36 questionnaire (Ware et al., 1996) . Two scores are generated from the SF-12, a Physical Composite Score (PCS) and a Mental Composite Score (MCS). These scores are generated using an algorithm which compares patients to a standardised otherwise well population normalised on a scale of 0-100 and mean (SD) PCS or MCS of 50(10). Scores below or above 50 for patients in the cohort confer higher or lower impact of long COVID on daily function relative to the standardised population. Although not validated for COVID-19 the score is well validated in a number of populations including US, UK, France, Germany, Sweden, Denmark, and a number of conditions including stroke, patients on dialysis, osteoarthritis, rheumatoid arthritis, acquired immunodeficiency syndrome, amongst other populations and conditions (Gandek et al., 1998 , Gandhi et al., 2001 , Han et al., 2002 , Johnson and Coons, 1998 , Lacson et al., 2010 , Lim and Fisher, 1999 

A total of 155 participants were included in the Anticipate Study, 105(68%) of whom were female with a median age of 43.3 (IQR 31-52) years and 150(96.8%) of whom were proven SARS-CoV2 PCR positive. Most participants were HCWs, n=97(60%), the largest subgroup of whom were student or staff nurses 52 (55.9%). The most common comorbidity for the cohort was hypertension (16.1%), Table 2 . Between 12 and 15 patients were seen in the clinic weekly, approximating to 300 patients attending the clinic during the enrolment period. In total 94 participants completed follow up at Timepoint 2, Figure 1 .

Symptoms at the time of initial infection were present in 152(98.1%) patients, symptoms and severity markers can be found in Table 2 . The median number of symptoms per patient was 3(IQR 2-5) and median time from symptom onset to swab positive result was 4 days(IQR 2-7). In total 11(7.1%) had radiological changes consistent with pneumonitis on X-ray or CT thorax. A total of 70(45%) patients were admitted to hospital for a median of 7 days (IQR 3-14 days), nine (13%, CI 5-21%) of whom required admission to intensive care.

Timepoint 1 (2-4 month follow up): Of 155, 149 completed a SF -12 questionnaire and had complete data from Timepoint 0, in the clinic setting at Timepoint 1 at a median of 96 days (IQR 76-118 days) from diagnosis. The composite scores PCS and MCS for the cohort during this period was significantly lower than a standardized population with mean(SD) PCS and MCS score of 50(10) (PCS, <0.001, MCS 0.002). PCS scores were significantly lower for older patients (40-59 years and 60+ years) p=0.001, and those hospitalised with COVID-19 at Timepoint 0, p=0.008. Overall MCS scores tended to be higher than PCS scores. Patients in intensive care had significantly higher MCS scores at 3 months than hospitalised patients not admitted to ICU, (52(11.4) vs 44(10.9), p=0.5), Appendix, Table 1 .

Timepoint 2 (7-14 month follow up): In total 94 patients completed second follow up at Timepoint 2. The median time to follow up was 364 days (IQR 303-398). For the whole cohort PCS did improve by over 2 points from the score at Timepoint 1 which was significant (42.96(10.9) -45.39(10.6), p= 0.02) but the score was still lower than the mean(50 (10) points) for the standardising population at Timepoint 2 (p= 0.001).MCS scores did not change significantly between Timepoint 1 and Timepoint 2 (p=0.311) and scores were similar to a standardised well population at Timepoint 2(p=0.699), Appendix, Table 2 .

Of 24(25.5%) of patients with ongoing symptoms at Timepoint 2, labelled PoCS, PCS scores were significantly lower at Timepoint 2 compared with those that had no symptoms (37.2(10.4) v 46.1(10.9) p <0.001). On retrospective review of PCS scores of these 24 patients at Timepoint 2, these patients had the lowest PCS scores within the symptomatic cohort (n=107(69%)) at Timepoint 1, furthermore there was no significant improvement across Timepoints 1 and 2 for this PoCS cohort (PCS 34.95(10.5) -37.2(10.4), p=.22).

Timepoint 2 can be seen in Figure 2 , data can be found in Appendix Table 2 . Patients who required hospitalisation did show lower MCS scores than COVID-19 patients who were never hospitalised (p=.043), and patients who had five or more symptoms at initial diagnosis had lower PCS and MCS scores at Timepoint 2 than those who had less than five symptoms(p=.036, p=.004).

Of the 57 HCWs who completed the second questionnaire at Timepoint 2 there was no difference in outcomes compared to other participants (PCS; 45.7(10.3) vs 44.6(11) p=0.795, MCS; 50(9.4) vs 46.9(9.7) p=0.102). Also, neither age, sex, nor ICU admission were factors that were associated with differences in PCS and MCS scores of participants at Timepoint 2, Figure 3 .

A total of 107(72%) patients had ongoing symptoms at Timepoint 1. The most common symptoms described were SOB (n=51(48%)), fatigue (n=44(41%)), and chest pain (n=16(15%), Table 3 . The median number of symptoms was 1 per patient (IQR 1-3).

Increased number of symptoms was associated with lower PCS scores (but not MCS scores), Appendix, Figure 1 .

Of the 24(25.5%) participants with PoCS at Timepoint 2, a reduction from 71(75.5%) at Timepoint 1was significant, p<.001. Also, the profile of symptoms differed at Timepoint 2.

Neurological issues including headache, anosmia, tinnitus, numbness, and paraesthesia were present in 10(37.5%) patients. Symptoms of fatigue (n=10(42%) and difficulties with concentration (n=8(33%)) were also common, Table 4 . The median number of symptoms was 2 (IQR 1-3) at Timepoint 2. Regarding presence of symptoms in HCWs compared with other participants, 65(70.7%) and 42(73.7%) had symptoms at Timepoint 1 p=0.689, also 18(31.6%) and 6(16.2%) had symptoms respectively at Timepoint 2 p=0.095. Bloods including full blood count, kidney and liver profile, C-reactive protein were done in these patients to screen for other potential causes. Repeat x-ray chests were done in 5 patients who previously had pneumonitis, all of which showed resolution of previous changes.

Univariate logistic regression was done to explore factors that may predict PoCS at Table 5 . Number of initial symptoms was nonsignificant in multivariable modelling (p=0.114) and excluded.

Overall, patients with PoCS at 1 year had significantly worse PCS scores compared to those without symptoms. PCS scores did not to improve significantly even at median follow up of 1 year in the PoCS cohort. A similar study of 96 patients showed symptoms of COVID-19 can persist for over 1 year and is associated with reduced SF-12 component scores compared to those without symptoms (PCS, p=0.006, MCS, p=0.031) (Seeßle et al., 2021) . Decreased physical function longitudinally has been reported elsewhere, Delbressine et al find significantly reduced self-reported walking time in 239 patients with PoCS 6 months after onset of symptoms . In general, studies examining HRQoL in long COVID patients are small; Logue et al. report ongoing symptoms in 24% of 177 patients at 9 months, 29% of whom report worse HRQoL compared with pre COVID-19 function (Logue et al., 2021) . Another study of 101 patients post hospitalisation with COVID-19 pneumonia showed significant reduction across all domains of SF-36 (excluding bodily pain) 6 weeks post infection(van der Sar-van der Brugge et al., 2021) . Although this study showed little improvement in the physical impact of COVID-19 at 1 year in those with ongoing symptoms, others have found small but significant increase in work productivity, functional status and quality of life despite a large burden of number of symptoms (median 6(3-8)) at 6 months, which offers some hope (Vaes et al., 2021) .

Overall MCS score were not as badly impacted as PCS scores. At Timepoint 2 MCS scores were not significantly different from an otherwise well population. Interestingly ICU patients at Timepoint 1 scored highest in MCS than any other sub-group. In a larger study exploring HRQoL in 294 COVID-19 patients, 40 of whom were admitted to ICU, a similar phenomenon was seen at 3 month follow up where ICU patients scored higher on a mental HRQoL than their non-ICU counterparts (Vlake et al., 2021) . The authors hypothesise that in the context of intubation and sedation the duration of psychological distress due to illness was reduced in these patients. The increase in MCS scores in ICU patients dissipated by 1 year follow up in this study (ICU v non-ICU p=.788). Overall hospitalised patients did have lower MCS scores at 1 year than non-hospitalised patients in this study.

Of the 94 patients who completed median 96 day and 364 day follow up, 71(75.5%) and 24(25.5%) of patients had PoCS respectively. Indicating that most symptomatic patients have resolution of symptoms by 1 year follow up post infection. Of these 24 patients with PoCS, symptoms tended to persist from the time of acute illness. Just 2(16.7%) patients initially reported no symptoms in the follow up clinic at a mean of 80 days post initial symptoms went on to report symptoms of difficulties concentrating or forgetfulness, subjectively described as 'brain fog' at Timepoint 2 follow up. The symptomatic profile of PoCS patients also changed over time from having predominately SOB and fatigue, to fatigue and neurological sequelae including difficulties concentrating. This highlights the nature of long COVID and that symptomatology is not dominated by single organ dysfunction. Fatigue was the most consistent symptom across both Timepoints 1 and 2, and has been reported elsewhere as a very common symptom of long COVID, 79% of individuals at 23 weeks reported severe fatigue in one cohort of a long covid support group, albeit this was improved from 87% at 10 weeks . Underlying mechanisms of persistent immune activation may be at the core of long COVID. Significantly higher ANA levels have been seen in patients with neurocognitive dysfunction compared with well counterparts over 1 year post onset of symptoms (Seeßle et al., 2021) . Aberrant mast cell activation, and autoimmune antibody production have been proposed as contributory inflammatory mechanisms to long COVID(Arthur et al., 2021 , Bertin et al., 2021 .

Lower PCS scores and higher resting HR levels at Timepoint 1 were predictive of PoCS at Timepoint 2. Early recognition of patients who may have a protracted course with PoCS is important to provide appropriate support and early referral to rehabilitation services to try to mitigate these effects. Large studies exploring potential predictors of long COVID have been done. Sudre CH et al. report female sex, increased BMI and having five or more initial symptoms as predictors in a cohort of over 4000 patients with self-reporting through a mobile application (Sudre et al., 2021) . They also show that simple modelling involving clustering of symptoms within seven days can also predict the development of PoCS. Although having five or more symptoms was not predictive of PoCS in this study, it was shown that patients certainly had lower PCS scores at one year.

Although studies exploring long COVID have relatively small sample sizes and are of short duration, there is clear and growing evidence that a certain proportion of those infected will go on to develop a potentially prolonged and debilitating illness irrespective of initial severity and baseline wellbeing. A very small number of studies including this study show that symptoms can persist, and the physical and mental impact of long COVID on daily living can be impaired for over 1 year in these patients.

The study is limited by small sample size from a single centre. Also, the cohort of 155 who were initially enrolled may not be representative of all patients after acute infection with COVID-19. For instance, many patients who did not have persistent symptoms may have felt there was no need to attend an out-patient service and were not contactable for follow up at Timepoint 2, also the cohort may be over-representative of patients with persistent symptoms. Furthermore, the majority of the cohort were HCWs, who may have experienced a greater amount of mental and physical stress than the general population, meaning that final outcomes may be an over-estimate of the impact of PoCS alone, although statistical significance was not found between HCWs and other patients in this study.

Potentially a larger sample size would have identified a significant difference between the two groups. Similarly, a number of variables showed a trend toward significance as predictor variables for the development of PoCS, i.e. the number of symptoms during acute COVID, a larger sample size may have also found these variables to be predictive, as larger studies have shown. Also, there were no baseline SF-12 questionnaires pre COVID-19, some individuals may have had lower scores at baseline due to comorbidities or other factors.

In summary patients with PoCS do not show significant improvement in PCS over a 1 year period and had significantly lower scores than study members who were asymptomatic at that time. In the weeks after acute infection higher HR and lower PCS scores may identify those that will have PoCS at 1 year and these patients should be targeted for prompt multidisciplinary intervention. The authors advise these tools be implemented for early screening of patients in the weeks after COVID-19 infection.

Research Ethics Committee (reference number: 1/378/2141).

The authors have no competing interests to declare. Post COVID-19 condition A history of probable or confirmed SARS CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms and that last for at least 2 months and cannot be explained by an alternative diagnosis. Hypercholestolaemia 18(11.6) 6.6-16.7

Chronic lung disease 17(11) 6-15.9 mood disorder 15(9.7) 5-14.3

Diabetes mellitus 12(7.7) 3.5-11.9

Gastrointestinal diagnosis 11(7.1) 3.1-11.1

Coronary artery disease 10(6.5) 2.6-10.3

Neurological diagnosis 9(5.8) 2.1-9.5

Rheumatological diagnosis 9(5.8) 2.1-9.5 Previous infection requiring hospitalisation 9(5.8) 2.1-9.5

Endocrinological diagnosis 8(5.2) 1.7-8.6

Malignancy 6(3.9) 0.8-6.9

Previous thromboembolism 5(3.2) 0-4.6 

Persistent IgG anti-cardiolipin autoantibodies are associated with post-covid syndrome

The Impact of Post-COVID-19 Syndrome on Self-Reported Physical Activity

Multi-organ impairment in lowrisk individuals with long

Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment

Psychometric evaluation of the 12-item short-form health survey (SF-12) in osteoarthritis and rheumatoid arthritis clinical trials

Huppler Hullsiek K, for the Terry Beirn Community Programs for Clinical Research on A. Assessing the utility of five domains in SF-12 Health Status Questionnaire in an AIDS clinical trial

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation

A Comparison of SF-36 and SF-12 Composite Scores and Subsequent Hospitalization and Mortality Risks in Long-Term Dialysis Patients

Use of the 12-item Short-Form (SF-12) Health Survey in an Australian heart and stroke population

Sequelae in Adults at 6 Months After COVID-19 Infection

More than 50 long-term effects of COVID-19: a systematic review and meta-analysis

Estimation de l'impact de la vaccination sur le risque de formes graves de Covid-19 chez les personnes de 50 à 74 ans en France à partir des données du Système National des Données de

Post-acute COVID-19 syndrome

National Institute for Health and Care Excellence: Clinical Guidelines. COVID-19 rapid guideline: managing the long-term effects of COVID-19

NIH. NIH launches new initiative to study "Long COVID

Persistent symptoms in adult patients one year after COVID-19: a prospective cohort study

Attributes and predictors of long COVID

Persistent Poor Health after COVID-19 Is Not Associated with Respiratory Complications or Initial Disease Severity

Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection

Recovery from COVID-19: a sprint or marathon? 6 months follow-up data of online long COVID-19 support group members

Pulmonary function and health-related quality of life after COVID-19 pneumonia

Severe Fatigue in Long COVID: Web-Based Quantitative Follow-up Study in Members of Online Long COVID Support Groups

Psychological distress and health-related quality of life in patients after hospitalization during the COVID-19 pandemic: A single-center, observational study

A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity

Mast cell activation symptoms are prevalent in Long-COVID

Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people

WHO. WHO Coronavirus (COVID-19) Dashboard

The authors have no competing interests to declare.